This PDF is the current document as it appeared on Public Inspection on 04/04/2014 at 08:45 am.
Food and Drug Administration, HHS.
Notification of withdrawal of approval; correction.
The Food and Drug Administration (FDA) published a document in the Federal Register of February 27, 2014, concerning the voluntary withdrawal of approval of new animal drug applications (NADAs). The document contained an incorrect list of NADAs.
This correction is effective April 7, 2014.Start Further Info
FOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, George.firstname.lastname@example.org.End Further Info End Preamble Start Supplemental Information
In FR Doc. 2014-02616, appearing on page 10974 in the Federal Register of February 27, 2014, the following corrections are made:
On page 10974, in the third column, in the 2d line of the “SUMMARY” section remove “69” and add in its place “68”.
On page 10975, the first bulleted text “Huvepharma AD, 5th Floor, 3A Nikolay Haitov Str., 1113 Sofia, Bulgaria has requested that FDA withdraw approval of the following 16 NADAs and 8 ANADAs” is corrected to read “Huvepharma AD, 5th Floor, 3A Nikolay Haitov Str., 1113 Sofia, Bulgaria, has requested that FDA withdraw approval of the following 15 NADAs and 8 ANADAs”; and on the same page in the table, the entry “013-461 3-NITRO (roxarsone)/AMPROL Plus (amprolium and ethopabate).” is removed.Start Signature
Dated: April 2, 2014.
Director, Center for Veterinary Medicine.
[FR Doc. 2014-07702 Filed 4-4-14; 8:45 am]
BILLING CODE 4160-01-P